{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'infusion of pegloticase will be defined as an AE. Other cases that occur outside of the 2-hour window may', 'also be categorized as an IR as per site PI discretion.', 'Anaphylaxis will be defined using the National Institute of Allergy and Infectious Diseases (NIAID)/ Food', 'Allergy and Anaphylaxis Network (FAAN) criteria: acute onset of an illness (minutes to several hours) with', 'involvement of the skin, mucosal tissue, or both (e.g., generalized hives; pruritus or flushing; urticarial, and', 'angioedema (of lips, tongue, or uvula) and at least one of the following:', \"Hypotension (i.e., systolic blood pressure < 90 mm Hg or > 30% decrease from that person's screening)\", 'or associated symptoms of end-organ failure (e.g., hypotonia [collapse], syncope, incontinence)', 'Respiratory compromise (e.g., dyspnea, bronchospasm, stridor, reduced peak expiratory flow,', 'hypoxemia)', 'Expected potential AEs Associated with Colchicine (see also section 2.3.1)', 'Participants taking colchicine for gout flare prophylaxis may experience gastrointestinal intolerance which may lead to', 'nausea, persistent diarrhea, and/or gastrointestinal bleeding. The most commonly reported side effects for the', 'prophylaxis of gout were diarrhea (23%) and pharyngolaryngeal pain (3%).', 'Other rare AEs associated with colchicine include:', 'Neutropenia, leading to an increased risk of infection', 'Anemia', 'Myalgia or myositis', 'Alopecia', 'Pruritus', 'Neuropathy', 'Oligospermia', 'While taking colchicine participants should avoid eating grapefruit and Seville oranges or drinking grapefruit juice or', 'Seville orange juice. Consumption can increase their chances of experiencing serious side effects.', '9.3.3.4 DEFINITION OF UNEXPECETED ADVERSE EVENTS (SAE)', 'An adverse event will be considered \"unexpected\" if it is not listed in the investigator brochure or is not listed at the', 'specificity or severity that has been observed; or, if it is not consistent with the risk information described in section', '9.3.3.3 of this study protocol.', '9.3.4 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP', 'The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of study personnel', 'during study visits and interviews of a study participant presenting for medical care, or upon review by the study', 'monitor (see section 11.1.7).', 'All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate case', \"report form (eCRF). Information to be collected includes event description, time of onset, clinician's assessment of\", 'severity, relationship to study drug (assessed only by those with the training and authority to make a diagnosis), and', 'time of resolution/stabilization of the event. All AEs occurring while on study drug will be documented appropriately', 'regardless of relationship. All AEs will be followed to adequate resolution.', 'Any medical condition that is present at the time that the participant is screened will be considered as baseline and not', \"reported as an AE. However, if the study participant's condition deteriorates at any time during the study, it will be\", 'recorded as an AE.', 'Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of', '29']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each', 'episode.', 'The study coordinator will record all reportable events with start dates occurring any time after informed consent is', 'obtained until 7 (for non-serious AEs) or 30 (for SAEs) days after the last day of study participation. At each study visit,', 'the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome', 'information until resolution or stabilization.', '9.3.5 ADVERSE EVENT REPORTING', 'We will report all serious AEs according to appropriate authority (e.g. IRB, NIAMS, FDA) in compliance with guidelines', 'and regulations established by the Data Safety Monitoring Board. See Appendix 9 Data Safety Monitoring Plan.', '9.3.6 SERIOUS ADVERSE EVENT REPORTING', 'We will immediately report to the DSMB and any serious adverse event, whether or not considered study intervention', 'related, including those listed in the protocol or investigator brochure and will include an assessment of whether in the', 'view of the site PI there is a reasonable possibility that the study intervention caused the event. Study endpoints that', 'are serious adverse events (e.g., all-cause mortality) will be reported in accordance with the protocol unless there is', 'evidence suggesting a causal relationship between the study intervention and the event (e.g., death from anaphylaxis).', 'In that case, the investigator will report the event to the NIAMS and DSMB via KAI within 48 hours of the investigator', 'becoming aware of the event.', 'All serious adverse events (SAEs) will be followed until satisfactory resolution or until the site investigator deems the', 'event to be chronic or the participant is stable. All SAEs, regardless of relatedness will be reported to the NIAMS and the', 'DSMB via KAI within 48 hours of becoming aware of the event. Supporting documentation of the event will be provided', 'by the DCC.', 'The Data Coordinating Center will be responsible for notifying the Institutional Review Board, Food and Drug', 'Administration (FDA), NIAMS/KAI, and any other body as mandated by the DSMB of any unexpected fatal or life-', 'threatening suspected adverse reaction within 24 hours. In addition, the Data Coordinating Center will notify FDA and', 'all participating investigators of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible,', 'but in no case later than 15 calendar days after it is determined that the information qualifies for reporting.', '9.3.7 REPORTING EVENTS TO PARTICIPANTS', 'Participants will be informed about new AEs and SAEs, and on conclusion of the study, study-related results at an', 'aggregate level.', '9.3.8 EVENTS OF SPECIAL INTEREST', '9.3.8.1 INFUSION REACTIONS (IRS)', 'As described in section 8.3.3.3 during pre-marketing controlled clinical trials, infusion reactions (IR) were reported in', '26% of patients treated with pegloticase 8 mg every 2 weeks. IRs will be defined as any infusion-related AE or cluster of', 'temporally-related AEs, not attributable to another cause, which occur during or within 2 hours after the infusion of', '30']\n\n###\n\n", "completion": "END"}